Syncona: Resolution Therapeutics and panCELLa Inc Announce Evaluation and Research Option Agreement to Develop iPSC-Derived Macrophage Cell Therapy for Inflammatory Organ Diseases
Grant Resolution an option on a commercial license for panCELLa’s FailSafe™ and iACT StealthCells™ technologies
London and Toronto, April 5, 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat advanced liver disease, and panCELLa Inc, (“panCELLa”) a private biotechnology company that manufactures cell lines incorporating therapeutic platform technologies cell-based therapies that are widely available for the treatment of degenerative, infectious and malignant diseases, today announced a research collaboration to develop iPSC-derived macrophage cell therapies. As part of this agreement, panCELLa provides its hypo-immunogenic iPSC technology to Resolution. Resolution uses its proprietary macrophage engineering and manufacturing technology to develop “off the shelf” macrophage cell therapies. As part of this agreement, Resolution has the opportunity to obtain commercial rights to use the panCELLa technology in the field of macrophage biology.
panCELLa, a specialist in the development of cell therapies for a wide range of diseases, provides safe therapeutic cell products. Under the terms of the collaboration, Resolution will have access to two of panCELLa’s platforms, FailSafeMT and induced allogeneic cell tolerance (iACT Stealth CellsMT), which paves the way for Resolution to advance the development of its allogeneic macrophage program, expanding the Company’s pipeline with iPSC-derived macrophages. This technology has the potential to guarantee long-term cell transplantation, which, in turn, could enable an unprecedented level of safety. Specifically, iACT Stealth CellsMT protect implanted cells of the patient’s immune system by providing long-term allogeneic tolerance without the need for immune suppression. Fail SafeMT is a top safety switch. Unlike others, it will not be lost or silenced because it is precisely related to cell division. Whenever cells deregulate or “go rogue,” they can be eliminated while allowing non-dividing therapeutic cells to continue doing their job.
“We are delighted to partner with panCELLA, a pioneer in the development of safe iPSC-derived cell therapies,” said Edward Hodgkin, Chairman and CEO of Resolution. “We believe that panCELLa’s technology has the potential to overcome the dual challenges of preventing host immune rejection of allogeneic cell therapy, while enhancing their safety, which will be critical to delivering lasting benefits to patients.” »
“The resolution technology and innovation is impressive and we believe in their plan for the development of macrophage cell therapy for advanced liver disease,” said Mahendra Rao, president of panCELLa“Resolution is well positioned to develop ready-to-use products that maintain optimal macrophage function with prevention of immune rejection, which are essential for persistent cell engraftment and clinical benefits.” »
Resolution is developing macrophage cell therapies to repair inflammatory organ damage, with a focus on treating end-stage chronic liver disease. Macrophages are cells of the innate immune system that orchestrate the body’s defense against infection and injury. the company builds on more than a decade of work in the founders’ labs characterizing the role of macrophages in organ repair, including the liver, in both preclinical and clinical settings.
panCELLa aims to make its therapeutic cell-based platform technologies widely available for the treatment of degenerative, infectious and malignant diseases. panCELLa continues its internal R&D efforts to develop additional new uses for its platform technologies in areas such as biomanufacturing, cancer vaccination and tolerization.
Terms of the collaboration were not disclosed.
– Ends –
Further information :
+44 (0)7818 430877
Notes for editors:
About the resolution
Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat advanced liver disease. The company builds on more than a decade of work in the founders’ labs characterizing the role of macrophages in organ repair, including the liver, in both preclinical and clinical settings. Resolution will discover, develop and bring to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes. www.resolution-tx.com
Founded in 2015, panCELLa is a private, early-stage biotechnology company based on innovative technology developed in the laboratory of Dr. Andras Nagy at Sinai Health System (SHS). panCELLa has created platforms that enable the development of safe, universal and “ready-to-use” cell lines. To learn more, visit https://pancella.com